• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

New, late-onset relapsing-remitting multiple sclerosis in a woman in her 60s after SARS-CoV-2 vaccination.

作者信息

Scorza Carla Alexandra, Scorza Fulvio Alexandre, Finsterer Josef

机构信息

Universidade Federal de São Paulo (UNIFESP/EPM), São Paulo, SP, Brazil.

Neurology Dpt., Neurology & Neurophysiology Center, Vienna, Austria.

出版信息

Clinics (Sao Paulo). 2024 Dec 13;80:100556. doi: 10.1016/j.clinsp.2024.100556. eCollection 2025.

DOI:10.1016/j.clinsp.2024.100556
PMID:39674029
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11699731/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/504f/11699731/fbb0aa34cbee/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/504f/11699731/fbb0aa34cbee/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/504f/11699731/fbb0aa34cbee/gr1.jpg

相似文献

1
New, late-onset relapsing-remitting multiple sclerosis in a woman in her 60s after SARS-CoV-2 vaccination.一名60多岁女性在接种新型冠状病毒疫苗后出现新发迟发性复发缓解型多发性硬化症。
Clinics (Sao Paulo). 2024 Dec 13;80:100556. doi: 10.1016/j.clinsp.2024.100556. eCollection 2025.
2
Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant?新冠病毒疫苗接种前后的多发性硬化症发病：HLA单倍型能否成为决定因素？
Int J Mol Sci. 2024 Apr 22;25(8):4556. doi: 10.3390/ijms25084556.
3
Antibodies against SARS-CoV-2 S and N proteins in relapsing-remitting multiple sclerosis patients treated with disease-modifying therapies.接受疾病修饰治疗的复发缓解型多发性硬化症患者体内针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白（S）和核衣壳蛋白（N）的抗体
Neurol Neurochir Pol. 2023;57(1):121-130. doi: 10.5603/PJNNS.a2022.0067. Epub 2022 Nov 24.
4
Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient.新冠病毒疫苗接种后利妥昔单抗治疗多发性硬化症患者的急性复发和免疫不良。
Hum Vaccin Immunother. 2021 Oct 3;17(10):3481-3483. doi: 10.1080/21645515.2021.1928463. Epub 2021 May 20.
5
SARS-CoV-2 triggered relapse of multiple sclerosis.SARS-CoV-2 引发多发性硬化症复发。
Clin Neurol Neurosurg. 2022 Apr;215:107210. doi: 10.1016/j.clineuro.2022.107210. Epub 2022 Mar 14.
6
The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.多发性硬化症的自然病史：基于地理的研究 10：复发和长期残疾。
Brain. 2010 Jul;133(Pt 7):1914-29. doi: 10.1093/brain/awq118. Epub 2010 Jun 9.
7
Natural history of multiple sclerosis: a unifying concept.多发性硬化症的自然史：一个统一的概念。
Brain. 2006 Mar;129(Pt 3):606-16. doi: 10.1093/brain/awl007. Epub 2006 Jan 16.
8
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study.迟发性和早发性复发缓解型多发性硬化症：来自回顾性长期随访研究的证据。
Eur J Neurol. 2018 Dec;25(12):1425-1431. doi: 10.1111/ene.13745. Epub 2018 Aug 3.
9
Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients.奥瑞珠单抗治疗的复发缓解型多发性硬化症患者单次接种 SARS-CoV-2 疫苗后血清转化率降低。
Mult Scler. 2022 Jun;28(7):1126-1130. doi: 10.1177/13524585211046786. Epub 2021 Oct 1.
10
Immune monitoring of SARS-CoV-2-specific T cell and B cell responses in patients with multiple sclerosis treated with ocrelizumab.奥瑞珠单抗治疗多发性硬化症患者的 SARS-CoV-2 特异性 T 细胞和 B 细胞反应的免疫监测。
Front Immunol. 2023 Sep 20;14:1254128. doi: 10.3389/fimmu.2023.1254128. eCollection 2023.

本文引用的文献

1
A case of hypophysitis after COVID-19 vaccination with a detection of anti-pituitary antibody, with review of literature.接种 COVID-19 疫苗后发生垂体炎，伴有垂体抗体检测，文献复习。
Endocr J. 2024 Aug 8;71(8):799-807. doi: 10.1507/endocrj.EJ24-0061. Epub 2024 May 3.
2
De novo IgA nephropathy in a kidney transplant recipient after SARS-CoV-2 vaccination.新型冠状病毒疫苗接种后肾移植受者发生的新发IgA肾病
Nefrologia (Engl Ed). 2024 Mar-Apr;44(2):277-279. doi: 10.1016/j.nefroe.2024.03.012. Epub 2024 Apr 18.
3
BNT162b2 COVID-19 vaccination in children alters cytokine responses to heterologous pathogens and Toll-like receptor agonists.
BNT162b2 新冠病毒疫苗接种改变了儿童对异源病原体和 Toll 样受体激动剂的细胞因子反应。
Front Immunol. 2023 Aug 25;14:1242380. doi: 10.3389/fimmu.2023.1242380. eCollection 2023.
4
Neurological Adverse Reactions to SARS-CoV-2 Vaccines.新型冠状病毒疫苗的神经不良反应
Clin Psychopharmacol Neurosci. 2023 May 30;21(2):222-239. doi: 10.9758/cpn.2023.21.2.222.
5
Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults.免疫衰老的迹象与老年人 mRNA COVID-19 疫苗接种效果不佳相关。
Nat Aging. 2022 Oct;2(10):896-905. doi: 10.1038/s43587-022-00292-y. Epub 2022 Oct 14.
6
New Onset Multiple Sclerosis Post-COVID-19 Vaccination and Correlation With Possible Predictors in a Case-Control Study.一项病例对照研究中新冠病毒疫苗接种后新发多发性硬化症及其与可能预测因素的相关性
Cureus. 2023 Mar 18;15(3):e36323. doi: 10.7759/cureus.36323. eCollection 2023 Mar.
7
New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure.在接触mRNA新冠疫苗的情况下新发多发性硬化症
J Neuroimmunol. 2022 Jan 15;362:577785. doi: 10.1016/j.jneuroim.2021.577785. Epub 2021 Dec 9.
8
First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.接种辉瑞-生物科技公司新冠疫苗后多发性硬化症的首发表现。
J Neurol. 2022 Jan;269(1):55-58. doi: 10.1007/s00415-021-10648-w. Epub 2021 Jun 11.